Sage Therapeutics’ stock dives as failed trial hits Biogen collaboration
Shares of Sage Therapeutics Inc. fell more than 18% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc.
Shares of Sage Therapeutics Inc. fell more than 18% premarket on Wednesday after a failed trial dealt a blow to the company’s collaboration with Biogen Inc.
